Group items tagged

Clinical Genomics Market By Test Type (Diagnostic, Genetic, Newborn Screening, Prenatal, Carrier Screening), Software, Method (Molecular, Chromosomal, Biochemical Tests), End User (Hospitals and Clinics) - Global Forecast to 2023

In Contempt of various potential advantages offered by way of modern technologies and capacities, the biopharmaceutical organization has commonly been slow to digitize its clinical trial process. Many biopharma corporations nowadays think about digital as a set of technology, structures, and superior analytics, which may include connected devices, mobile applications, artificial intelligence (AI), and robotics. The first-moving organization is also typically focusing on the fragmented solution and piloting technologies in exclusive areas of clinical trial and development to aid the existing scenario.

Many newly diagnosed prostate cancers present as low Gleason score tumors that require no treatment intervention. Distinguishing the many indolent tumors from the minority of lethal ones remains a major clinical challenge. We now show that low Gleason score prostate tumors can be distinguished as indolent and aggressive subgroups on the basis of their expression of genes associated with aging and senescence. Using gene set enrichment analysis, we identified a 19-gene signature enriched in indolent prostate tumors. We then further classified this signature with a decision tree learning model to identify three genes-FGFR1, PMP22, and CDKN1A-that together accurately predicted outcome of low Gleason score tumors. Validation of this three-gene panel on independent cohorts confirmed its independent prognostic value as well as its ability to improve prognosis with currently used clinical nomograms. Furthermore, protein expression of this three-gene panel in biopsy samples distinguished Gleason 6 patients who failed surveillance over a 10-year period. We propose that this signature may be incorporated into prognostic assays for monitoring patients on active surveillance to facilitate appropriate courses of treatment.

Visit Trivedi Science, a unique science on the planet, to read clinical studies by Mahendra Trivedi.

Medicines and healthcare are synonymous globally. As treatments become more innovative, to address unmet clinical needs, it is important that there is innovation in the pharma value chain as well. In order that patients receive the right medicine, at the right time and the right place, there is a need for a complex value chain. The full set of activities that occur prior to a patient receiving a medicine, constitute the pharmaceutical value chain. This value would differ within markets and also between markets. https://www.acldigital.com/blogs/top-10-data-integration-and-management-challenges-pharma-value-chain

"The results are published in Nature Medicine today. Co-author Stanley Hazen, head of cardiovascular medicine at the Cleveland Clinic in Ohio, says that the study could signal a new approach to diet and health. In some cases, an individual's collection of intestinal microbes may be as important to their diet as anything on a nutrition label, he says. "Bacteria make a whole slew of molecules from food," he says, "and those molecules can have a huge effect on our metabolic processes.""

"Nature: "A group called DIYgenomics has banded together to analyse their genomes, and even conduct and participate in small clinical trials" - October 2010 Nature Medicine: "...early adopters are showing how empowering and beneficial to science personal genetic information can be" - September 2010 WIRED: "...they wanted to build a model trial that could be easily replicated by citizen scientists anywhere" "

""We probably have underestimated the role our microbial flora play in modulating disease risk," says Daniel Rader, a heart disease specialist at the University of Pennsylvania School of Medicine. Rader, who was not involved in the study, says that gut bacteria may not be as big a factor in causing heart disease as diabetes or smoking, but could be important in tipping some people toward sickness. Researchers led by Stanley Hazen, a cardiologist at the Cleveland Clinic, didn't start out to study gut bacteria. In fact, says Hazen, he had "no clue - zero," that intestinal microbes were involved in heart disease. "I'd never even considered it or thought of the concept." Hazen and his colleagues compared blood plasma from healthy people to plasma from people who had had heart attacks, strokes or died to see if substances in the blood could predict who is in danger from heart disease. The researchers found 18 small molecules associated with fat buildup in the arteries. One of the best predictors turned out to be a byproduct made when gut bacteria break down a fat called choline (also known as lecithin). The more of this byproduct, called trimethylamine N-oxide or TMAO, a person or mouse has in the blood, the higher the risk of getting heart disease, the researchers found. Gut bacteria are actually middlemen in TMAO production. The microbes convert lecithin to a gas that smells like rotten fish. Then an enzyme in the liver changes the foul-smelling gas to TMAO."

"The results are indeed worthy of attention, with Prof Taylor's team finding that in an early stage clinical trial of 11 people who were put on a diet of just 600 calories As written about in Dr Ben Goldacre's latest Bad Science column, producing a pattern from experimental data to come to a conclusion can be a 'magical' experience, but medicine is an 'imperfect art'. "We all know one atom of experience isn't enough to spot a pattern." writes Goldacre, "But when you put lots of experiences together and process that data, you get new knowledge.""

"ScienceDaily (Aug. 25, 2010) - A new study from researchers in Canada and Sweden has shown that biosynthetic corneas can help regenerate and repair damaged eye tissue and improve vision in humans. The results, from an early phase clinical trial with 10 patients, are published in the August 25th, 2010 issue of Science Translational Medicine"

In the first clinical proof of its kind, a drug has dramatically shrunk cancerous tumors by disrupting a key genetic pathway. But a study targeting one deadly brain cancer, medulloblastoma, ended in disappointment as the patient's once-tamed tumor quickly developed resistance to the drug and killed him.

"Clinics that offer to "bank" stem cells from the umbilical cords of newborns for use later in life when illness strikes are fraudsters, a top US scientist said here Saturday."

Purpose of review: Autism is a biologically based disorder of brain development. Genetic factors - mutations, deletions, and copy number variants - are clearly implicated in causation of autism. However, they account for only a small fraction of cases, and do not easily explain key clinical and epidemiological features. This suggests that early environmental exposures also contribute. This review explores this hypothesis. Recent findings: Indirect evidence for an environmental contribution to autism comes from studies demonstrating the sensitivity of the developing brain to external exposures such as lead, ethyl alcohol and methyl mercury. But the most powerful proof-of-concept evidence derives from studies specifically linking autism to exposures in early pregnancy - thalidomide, misoprostol, and valproic acid; maternal rubella infection; and the organophosphate insecticide, chlorpyrifos. There is no credible evidence that vaccines cause autism. Summary: Expanded research is needed into environmental causation of autism. Children today are surrounded by thousands of synthetic chemicals. Two hundred of them are neurotoxic in adult humans, and 1000 more in laboratory models. Yet fewer than 20% of high-volume chemicals have been tested for neurodevelopmental toxicity. I propose a targeted discovery strategy focused on suspect chemicals, which combines expanded toxicological screening, neurobiological research and prospective epidemiological studies.

ScienceDaily (May 9, 2011) - Mayo Clinic researchers have designed a new tool for identifying protein function from genetic code. A team led by Stephen Ekker, Ph.D., succeeded in switching individual genes off and on in zebrafish, then observing embryonic and juvenile development. The study appears in the journal Nature Methods.

Scientists at the McEwen Centre for Regenerative Medicine and the Ontario Cancer Institute have isolated a human blood stem cell in its purest form: as a single stem cell capable of regenerating the entire blood system. "This discovery means we now have an increasingly detailed road map of the human blood development system, including the much sought after stem cell," says principal investigator John Dick, who holds a Canada Research Chair in Stem Cell Biology and is a Senior Scientist at the McEwen Centre for Regenerative Medicine and the Ontario Cancer Institute, University Health Network (UHN). "We have isolated a single cell that makes all arms of the blood system, which is key to maximizing the potential power of stem cells for use in more clinical applications. Stem cells are so rare that this is a little like finding a needle in a haystack," says Dr. Dick. Ref.: John E. Dick, Isolation of Single Human Hematopoietic Stem Cells Capable of Long-Term Multilineage Engraftment, Science, July 2011: Vol. 333 no. 6039 pp. 218-221 [DOI: 10.1126/science.1201219]

The unique physiology of Mahendra Trivedi has been studied and documented extensively in the USA, Australia, Canada and India by renowned clinical specialists and scientists.

"The BioMed X Innovation Center is an exciting new collaboration model at the interface between academia and industry. At our center, distinguished early career scientists recruited from all over the world are working jointly on novel pre-clinical research projects in the fields of biomedicine, molecular biology, cell biology, diagnostics, bioinformatics, neuroscience and nanomaterials. These interdisciplinary project teams are conducting outstanding biomedical research in an open innovation lab facility on the campus of the University of Heidelberg"